NCT05718934View on ClinicalTrials.gov

Low Dose of Sugammadex vs Neostigmine and Glycopyrrolate for the Reversal of Rocuronium

PHASE4CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Neuromuscular Blockade
Interventions
DRUG

Neostigmine and glycopyrrolate

See arm descriptions

DRUG

Sugammadex

See arm descriptions

Trial Locations (1)

H1T2M4

CIUSSS de l'Est de l'Ile de Montreal, Montreal

All Listed Sponsors
lead

Ciusss de L'Est de l'Île de Montréal

OTHER